At Fluxion, we’re committed to developing liquid biopsy tests that provide non-invasive diagnosis of each patient’s cancer. Our goal is to deliver blood tests that provide an accurate, sensitive cancer molecular profile, leading to better treatment decisions and improved patient outcomes.

Fluxion’s liquid biopsy solutions are used globally by leading research centers in the development of novel assays for early cancer detection, therapy selection, and patient monitoring.